Citius Pharmaceuticals Inc (NASDAQ:CTXR) insider Leonard L. Mazur acquired 421,400 shares of the company’s stock in a transaction on Tuesday, August 8th. The shares were purchased at an average cost of $4.13 per share, with a total value of $1,740,382.00. Following the completion of the purchase, the insider now directly owns 1,779,663 shares of the company’s stock, valued at $7,350,008.19. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Citius Pharmaceuticals Inc (NASDAQ:CTXR) opened at 2.91 on Friday. The stock’s market capitalization is $14.65 million. Citius Pharmaceuticals Inc has a 1-year low of $2.75 and a 1-year high of $25.65. The firm’s 50-day moving average is $6.44 and its 200 day moving average is $6.34.
TRADEMARK VIOLATION WARNING: “Leonard L. Mazur Buys 421,400 Shares of Citius Pharmaceuticals Inc (NASDAQ:CTXR) Stock” was published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.com-unik.info/2017/08/12/leonard-l-mazur-buys-421400-shares-of-citius-pharmaceuticals-inc-nasdaqctxr-stock.html.
About Citius Pharmaceuticals
Citius Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream.
What are top analysts saying about Citius Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Citius Pharmaceuticals Inc and related companies.